Pharma News

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials.

India is preparing to expand its pharmaceutical exports to Russia, Brazil, and the Netherlands, seeking to diversify its markets beyond the United States

Zydus Lifesciences Ltd., a global innovation led healthcare company, today announced the launch of its trivalent influenza (Flu) vaccine VaxiFluTM introduced for the first time in India, aligning with the global recommendations of WHO.

The US Food and Drug Administration, FDA, has approved Wayrilz, rilzabrutinib for adults with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.

The Ministry of Health & Family Welfare through National Rabies Control Program (NRCP) is undertaking strengthening of surveillance of all animal bites in all States/UTs. Data on dog and other animal bite cases and related deaths are reported by all States/UTs, through Integrated Health Information Platform

Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, highlighted Indias transformation into an emerging hub for medical technology at the 17th CII Global MedTech Summit, themed Innovating for a Healthier Future – Advancing MedTech for Global Impact: Make in India, Make for the World, in New Delhi.

The Subject Expert Committee Oncology, in its 25th meeting held at CDSCO headquarters, has recommended granting permission to Bayer Pharmaceuticals Pvt. Ltd. for the manufacture and marketing of Darolutamide Film-Coated Tablets 300 mg in India.

Positive full results from the ​BaxHTN Phase III trial showed AstraZeneca ​baxdrostat, demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses 2mg and 1mg compared with placebo at 12 weeks. Results were seen in patients with hard-to-control uncontrolled and resistant hypertension who received baxdrostat or placebo on top of standard of care.